![conference banner](/images/conference-banner.jpeg)
Abstract
Positron emission tomography (PET) is one of the most rapidly growing areas of medical imaging for cancer research. The principal goal of PET imaging is to visualize, characterize, and measure biological processes at the molecular and cellular levels in living subjects using non-invasive procedures. Taking advantage of the traditional diagnostic imaging techniques, PET imaging introduces positron-emitting probes to determine the expression of indicative molecular targets at different stages of cancer progression. As a key component of PET technique, an appropriate imaging probe must be able to specifically reach the target of interest in vivo while retaining in the target within reasonable time to be detected. Over the last decade, numerous target-specific PET probes have been developed and evaluated in preclinical and clinical studies. This review provides an overview of recent advances made in PET imaging of cancer biology with a focus on the best-studied biological targets. The trends in developing future PET imaging probes are also discussed.
Keywords: Angiogenesis, cancer, Cell death, Cell proliferation, Hypoxia, Molecular imaging probe, Positron emission tomography (PET).
Current Topics in Medicinal Chemistry
Title:Development of PET Probes for Cancer Imaging
Volume: 15 Issue: 8
Author(s): Rui Huang, Mingwei Wang, Yizhou Zhu, Peter S. Conti and Kai Chen
Affiliation:
Keywords: Angiogenesis, cancer, Cell death, Cell proliferation, Hypoxia, Molecular imaging probe, Positron emission tomography (PET).
Abstract: Positron emission tomography (PET) is one of the most rapidly growing areas of medical imaging for cancer research. The principal goal of PET imaging is to visualize, characterize, and measure biological processes at the molecular and cellular levels in living subjects using non-invasive procedures. Taking advantage of the traditional diagnostic imaging techniques, PET imaging introduces positron-emitting probes to determine the expression of indicative molecular targets at different stages of cancer progression. As a key component of PET technique, an appropriate imaging probe must be able to specifically reach the target of interest in vivo while retaining in the target within reasonable time to be detected. Over the last decade, numerous target-specific PET probes have been developed and evaluated in preclinical and clinical studies. This review provides an overview of recent advances made in PET imaging of cancer biology with a focus on the best-studied biological targets. The trends in developing future PET imaging probes are also discussed.
Export Options
About this article
Cite this article as:
Huang Rui, Wang Mingwei, Zhu Yizhou, Conti S. Peter and Chen Kai, Development of PET Probes for Cancer Imaging, Current Topics in Medicinal Chemistry 2015; 15 (8) . https://dx.doi.org/10.2174/1568026615666150302110325
DOI https://dx.doi.org/10.2174/1568026615666150302110325 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
“Antisurvival” Factor Treatment for Hormone Refractory Prostate Cancer: Secondary Hormonal Ablation Using Somatostatin Analogs
Current Cancer Therapy Reviews Adenocarcinoma of the Appendix in Elderly: Diagnostic Dilemma
New Emirates Medical Journal A Critical View of Molecularly Target Therapy for Digestive Endocrine Tumours
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The ECL Cell: Relay Station for Gastric Integrity
Current Medicinal Chemistry Clinicopathological Characteristics of Chinese Colorectal Cancer Patients under 30 Years of Age: Implication in Diagnosis and Therapy
Current Cancer Drug Targets Comparative Studies of the Chromogranin A-Derived Neuropeptide WE-14
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents An Updated Patent Therapeutic Agents Targeting MMPs
Recent Patents on Anti-Cancer Drug Discovery Editorial from Guest Editor (DNA Methylation: A Target for Current and Future Therapies?)
Epigenetic Diagnosis & Therapy (Discontinued) MiRNA-145 and Its Direct Downstream Targets in Digestive System Cancers: A Promising Therapeutic Target
Current Pharmaceutical Design The Role of 5-HT1A Receptor in Cancer as a New Opportunity in Medicinal Chemistry
Current Medicinal Chemistry MicroRNAs in Non-small Cell Lung Cancer: Current Status and Future Therapeutic Promises
Current Pharmaceutical Design The Macrophage Stimulating Protein/Ron Pathway as a Potential Therapeutic Target to Impede Multiple Mechanisms Involved in Breast Cancer Progression
Current Drug Targets Novel Drug-Induced Pulmonary Complications in Cancer Patients You Can Save Life!
Current Respiratory Medicine Reviews Serum Procalcitonin Levels in Febrile Patients with Systemic Autoimmune Diseases
Current Rheumatology Reviews Small Peptide and Protein-based Molecular Probes for Imaging Neurological Diseases
Current Protein & Peptide Science Stress Related Neuroendocrine Influences in Ovarian Cancer
Current Cancer Therapy Reviews Thematic Analysis™ : A Chemogenomic Approach to GPCR Drug Discovery
Current Topics in Medicinal Chemistry Molecular Approach to Targeted Therapy for Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets New Insight into 2-Methoxyestradiol- a Possible Physiological Link between Neurodegeneration and Cancer Cell Death
Current Medicinal Chemistry The Innate Immunity: Roles for New Antifungal and Antibacterial Peptides Secreted by Chromaffin Granules from the Adrenal Medulla
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents